JP Morgan Initiates Coverage On Shattuck Labs with Overweight Rating, Announces Price Target of $10
Leerink Partners Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $16
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update - Slideshow
What's Going On With Shattuck Labs Stock Wednesday?
Shattuck Labs: "Hold" On Phase 1 SL-325 Data And Next Stage Of Development
Shattuck Labs Commences Common Stock Offering; Terms Undisclosed
Citigroup Maintains Buy on Shattuck Labs, Raises Price Target to $18
Shattuck Labs Announces Total Expected Proceeds Of ~$59.4M From Exercised Warrants
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript
Why Is Shattuck Labs Stock Trading Lower On Monday?
Needham Maintains Buy on Shattuck Labs, Raises Price Target to $17
HC Wainwright & Co. Reiterates Buy on Shattuck Labs, Maintains $18 Price Target
Shattuck Reports Phase 1 Data for SL-325 Antibody
Shattuck Labs To Host Investor Call And Webcast On June 8 To Present Comprehensive Phase 1 Clinical Data For SL-325 And Provide Pipeline Update
Citigroup Upgrades Shattuck Labs to Buy, Announces $7 Price Target
Shattuck Labs: Priced As If Risk Was Not A Part Of The Equation
We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
Wedbush Maintains Outperform on Shattuck Labs, Raises Price Target to $11
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
Shattuck Labs Q1 EPS $(0.13), Inline
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.